{{PBB|geneid=335}}
'''載脂蛋白A1'''（{{lang-en|Apolipoprotein A1}}，簡稱'''ApoA1'''）為附著於[[高密度脂蛋白|高密度脂蛋白]]（HDL）及[[乳靡小球|乳靡小球]]上的[[載脂蛋白|載脂蛋白]]，基因編碼為「''APOA1''」<ref name="pmid6294659">{{vcite2 journal | vauthors = Breslow JL, Ross D, McPherson J, Williams H, Kurnit D, Nussbaum AL, Karathanasis SK, Zannis VI | title = Isolation and characterization of cDNA clones for human apolipoprotein A-I | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 79 | issue = 22 | pages = 6861–5 | date = November 1982 | pmid = 6294659 | pmc = 347233 | doi = 10.1073/pnas.79.22.6861 }}</ref><ref name="pmid1972696">{{vcite2 journal | vauthors = Arinami T, Hirano T, Kobayashi K, Yamanouchi Y, Hamaguchi H | title = Assignment of the apolipoprotein A-I gene to 11q23 based on RFLP in a case with a partial deletion of chromosome 11, del(11)(q23.3----qter) | journal = Hum. Genet. | volume = 85 | issue = 1 | pages = 39–40 | date = June 1990 | pmid = 1972696 | doi = 10.1007/BF00276323 }}</ref>。載脂蛋白A1可以活化{{le|卵磷脂-胆固醇酰基转移酶|Lecithin—cholesterol acyltransferase}}（Lecithin Cholesterol Acyltransferase，LCAT）；當[[高密度脂蛋白|高密度脂蛋白]]運送[[组织_(生物学)|組織]]中多餘的[[膽固醇|膽固醇]]回到[[肝臟|肝臟]][[細胞|細胞]]中時，載脂蛋白A1同時也可作為高密度脂蛋白的[[配體|配體]]，在{{tsl|en|lipid metabolism|脂質代謝}}中扮演重要角色。研究指出，''APOA1''的mRNA是由反義RNA轉譯出的內源性蛋白質所調控<ref>{{vcite2 journal | vauthors = Halley P, Kadakkuzha BM, Faghihi MA, Magistri M, Zeier Z, Khorkova O, Coito C, Hsiao J, Lawrence M, Wahlestedt C | title = Regulation of the Apolipoprotein Gene Cluster by a Long Noncoding RNA | journal = Cell Reports | volume = 6 | issue = 1 | pages = 222–230 | date = 16 January 2014 | pmid = 24388749 | doi = 10.1016/j.celrep.2013.12.015 }}</ref>。

==結構==
APOA1基因位於第11對染色體上（11q23-q24），該基因包含4個外顯子<ref name="entrez" />。载脂蛋白A1的質量為45.4 kDa ，含有 396 個胺基酸；質譜分析可觀察到蛋白質由21個胜肽片段組成<ref name=COPaKB>]{{cite journal | vauthors = Zong NC, Li H, Li H, Lam MP, Jimenez RC, Kim CS, Deng N, Kim AK, Choi JH, Zelaya I, Liem D, Meyer D, Odeberg J, Fang C, Lu HJ, Xu T, Weiss J, Duan H, Uhlen M, Yates JR, Apweiler R, Ge J, Hermjakob H, Ping P | title = Integration of cardiac proteome biology and medicine by a specialized knowledgebase | journal = Circulation Research | volume = 113 | issue = 9 | pages = 1043–53 | date = Oct 2013 | pmid = 23965338 | pmc = 4076475 | doi = 10.1161/CIRCRESAHA.113.301151 }}</ref><ref name="url_COPaKB">{{cite web | url = http://www.heartproteome.org/copa/ProteinInfo.aspx?QType=Protein%20ID&QValue=QP06727 | work = Cardiac Organellar Protein Atlas Knowledgebase (COPaKB) | title = Apolipoprotein A-IV }}{{dead link|date=2018年1月 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>。

==功能==
載脂蛋白A1（ApoA1）為構成血漿中[[高密度脂蛋白|高密度脂蛋白]]（HDL）蛋白質部分的主要成分。小腸腸道細胞所分泌的[[乳糜微粒|乳糜微粒]]中雖然也含有載脂蛋白A1，但在血流中很快就會被轉為HDL<ref name="pmid18079757">{{cite journal | vauthors = Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ | title = Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery | journal = Nature Reviews Drug Discovery | volume = 7 | issue = 1 | pages = 84–99 | date = January 2008 | pmid = 18079757 | doi = 10.1038/nrd2353 }}</ref>。ApoA1可促進將周邊組織脂質及[[膽固醇|膽固醇]]回收至[[肝臟|肝臟]]，並藉由膽管分泌至小腸。另外該蛋白也是{{tsl|en|Lecithin—cholesterol acyltransferase|卵磷脂-胆固醇酰基转移酶}}（LCAT）的輔因子，製造了血漿中大多數的{{tsl|en|cholesteryl esters|膽固醇脂}}。ApoA1同時也是[[前列环素|前列环素]]（PGI2）的穩定因子，因此也具有抗凝血的作用<ref>{{cite journal | vauthors = Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C | title = Serum prostacyclin stabilizing factor is identical to apolipoprotein A1 (apo A1). A novel function of apo A1 | journal = J. Clin. Invest. | volume = 82 | issue = 3 | pages = 803–7 | year = 1988 | pmid = 3047170 | pmc = 303586 | doi = 10.1172/JCI113682 }}</ref>。如果編碼該蛋白的基因有缺陷，會導致個體體內缺乏HDL，導致包含{{tsl|en|Tangier disease|Tangier disease}}在內的症狀，以及非神經性全身[[淀粉样变|類澱粉變性]]<ref name=entrez>{{cite web |title = Entrez Gene: APOA1 apolipoprotein A1| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=335| accessdate = }}</ref>。

由於ApoA1在體內脂質代謝的角色相當重要，因此常被視為預測個體冠心病風險的生物標記。有研究發現「apoB-100/apoA1」的比值預測[[心肌梗塞|心肌梗塞]]的效果比任何其他脂質標記更有效果<ref name="bindingofhdl">{{cite journal | vauthors = McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S | title = Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study | journal = Lancet | volume = 372 | issue = 9634 | pages = 224–33 | year = 2008 | pmid = 18640459 | doi = 10.1016/S0140-6736(08)61076-4 }}</ref>。ApoA1可利用[[酶联免疫吸附试验|ELISA]]或{{tsl|en|nephelometry||nephelometry}}檢驗。

==臨床意義==
{{TransH}}
=== Activity associated with high HDL-C and protection from heart disease ===

As a major component of the [[高密度脂蛋白|high-density lipoprotein]] complex ('''protective "fat removal" particles'''), apo A1 helps to clear fats, including [[膽固醇|cholesterol]], from white blood cells within artery walls, making the WBCs less likely to become fat overloaded, transform into foam cells, die and contribute to progressive {{tsl|en|atheroma||atheroma}}.  Five of nine men found to carry a mutation (E164X) who were at least 35 years of age had developed premature [[冠狀動脈疾病|coronary artery disease]].<ref name="pmid16023124">{{cite journal | vauthors = Dastani Z, Dangoisse C, Boucher B, Desbiens K, Krimbou L, Dufour R, Hegele RA, Pajukanta P, Engert JC, Genest J, Marcil M | title = A novel nonsense apolipoprotein A-I mutation (apoA-I(E136X)) causes low HDL cholesterol in French Canadians | journal = Atherosclerosis | volume = 185 | issue = 1 | pages = 127–36 | date = March 2006 | pmid = 16023124 | doi = 10.1016/j.atherosclerosis.2005.05.028 }}</ref>One of four mutants of apo A1 is present in roughly 0.3% of the Japanese population, but is found in 6% of those with low HDL cholesterol levels.

'''{{tsl|en|ApoA-1 Milano||ApoA-1 Milano}}''' is a naturally occurring mutant of apo A1, found in a few families in [[利莫内苏尔加尔达|Limone sul Garda]], Italy, and, by genetic + church record family tree detective work, traced to a single individual in the 14th century. Described in 1980, it was the first known molecular abnormality of [[载脂蛋白|apolipoprotein]]s.<ref name="pmid6785551">{{cite journal | vauthors = Franceschini G, Sirtori M, Gianfranceschi G, Sirtori CR | title = Relation between the HDL apoproteins and A-I isoproteins in subjects with the AIMilano abnormality | journal = Metab. Clin. Exp. | volume = 30 | issue = 5 | pages = 502–9 | date = May 1981 | pmid = 6785551 | doi = 10.1016/0026-0495(81)90188-8 }}</ref>Paradoxically, carriers of this mutation have very low HDL-C (HDL-Cholesterol) levels, but no increase in the risk of heart disease, often living to age 100 or older. This unusual observation was what lead Italian investigators to track down what was going on and lead to the discovery of apo A1 Milano (the city, Milano, ~160 km away, in which the researcher's lab was located). Biochemically, apo A1 contains an extra [[半胱氨酸|cysteine]] bridge, causing it to exist as a [[蛋白二聚体|homodimer]] or as a [[蛋白二聚体|heterodimer]] with apo A-II.  However, the enhanced cardioprotective activity of this mutant (which likely depends on fat & cholesterol efflux) cannot easily be replicated by other cysteine mutants.<ref>{{cite journal | vauthors = Zhu X, Wu G, Zeng W, Xue H, Chen B | title = Cysteine mutants of human apolipoprotein A-I: a study of secondary structural and functional properties | journal = J. Lipid Res. | volume = 46 | issue = 6 | pages = 1303–11 | year = 2005 | pmid = 15805548 | doi = 10.1194/jlr.M400401-JLR200 }}</ref>

Recombinant apo A1 Milano dimers formulated into liposomes can reduce {{tsl|en|atheroma||atheroma}}s in animal models by up to 30%.<ref>{{cite journal | vauthors = Chiesa G, Sirtori CR | title = Apolipoprotein A-I(Milano): current perspectives | journal = Curr. Opin. Lipidol. | volume = 14 | issue = 2 | pages = 159–63 | year = 2003 | pmid = 12642784 | doi = 10.1097/00041433-200304000-00007 }}</ref>Apo A1 Milano has also been shown in small clinical trials to have a statistically significant effect in reducing (reversing) plaque build-up on arterial walls.<ref name="cleveland_clinic">{{cite web | url = http://www.clevelandclinic.org/heartcenter/pub/news/hot/hdlapoa1.asp?firstCat=1&secondCat=429&thirdCat=602 | title = Apo A-I-Milano Trial: Where are we now? | publisher = Cleveland Clinic | pages = | archiveurl = | archivedate = | quote = | accessdate = 2008-07-26}}</ref><ref name="pmid14600188">{{cite journal | vauthors = Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R | title = Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial | journal = JAMA | volume = 290 | issue = 17 | pages = 2292–300 | date = November 2003 | pmid = 14600188 | doi = 10.1001/jama.290.17.2292 }}</ref>

In human trials the reversal of plaque build-up was measured over the course of five weeks.<ref name="cleveland_clinic" /><ref name="cedars-sinai">{{cite web |url=http://www.cedars-sinai.edu/pf_6189.html |title=Apo A-I Milano |publisher=Cedars-Sinai Heart Institute |accessdate=2008-07-26 |deadurl=yes |archiveurl=https://web.archive.org/web/20071221232928/http://www.cedars-sinai.edu/pf_6189.html |archivedate=21 十二月 2007 }}</ref>

===Novel Haplotypes within apolipoprotein AI-CIII-AIV gene cluster===
Lately, two novel susceptibility haplotypes i.e. P2-S2-X1 and P1-S2-X1 have been discovered in ApoAI-CIII-AIV gene cluster on chromosome 11q23, which confer approximately threefold higher risk of coronary heart disease in normal<ref name="pmid17825930">{{cite journal | vauthors = Singh P, Singh M, Kaur TP, Grewal SS | title = A novel haplotype in ApoAI-CIII-AIV gene region is detrimental to Northwest Indians with coronary heart disease | journal = Int. J. Cardiol. | volume = 130 | issue = 3 | pages = e93–5 | date = September 2007 | pmid = 17825930 | doi = 10.1016/j.ijcard.2007.07.029 }}</ref>as well as in the patients having non-insulin diabetes mellitus.<ref name="pmid17654446">{{cite journal | vauthors = Singh P, Singh M, Gaur S, Kaur T | title = The ApoAI-CIII-AIV gene cluster and its relation to lipid levels in type 2 diabetes mellitus and coronary heart disease: determination of a novel susceptible haplotype | journal = Diab Vasc Dis Res | volume = 4 | issue = 2 | pages = 124–9 | date = June 2007 | pmid = 17654446 | doi = 10.3132/dvdr.2007.030 }}</ref>

=== Role in other diseases ===

A G/A [[多态性_(生物学)|polymorphism]] in the [[啟動子|promoter]] of the apo A1 gene has been associated with the age at which patients presented with [[阿兹海默病|Alzheimer disease]].<ref>{{cite journal | vauthors = Vollbach H, Heun R, Morris CM, Edwardson JA, McKeith IG, Jessen F, Schulz A, Maier W, Kölsch H | title = APOA1 polymorphism influences risk for early-onset non-familial AD | journal = Ann. Neurol. | volume = 58 | issue = 3 | pages = 436–41 | year = 2005 | pmid = 16130094 | doi = 10.1002/ana.20593 }}</ref>Protection from Alzheimer's disease by apo A1 may rely on a synergistic interaction with {{tsl|en|alpha-tocopherol||alpha-tocopherol}}.<ref>{{cite journal | vauthors = Maezawa I, Jin LW, Woltjer RL, Maeda N, Martin GM, Montine TJ, Montine KS | title = Apolipoprotein E isoforms and apolipoprotein A-I protect from amyloid precursor protein carboxy terminal fragment-associated cytotoxicity | journal = J. Neurochem. | volume = 91 | issue = 6 | pages = 1312–21 | year = 2004 | pmid = 15584908 | doi = 10.1111/j.1471-4159.2004.02818.x }}</ref>
[[類澱粉蛋白|Amyloid]] deposited in the knee following surgery consists largely of apo A1 secreted from [[软骨细胞|chondrocytes]] ([[软骨|cartilage]] cells).<ref>{{cite journal | vauthors = Solomon A, Murphy CL, Kestler D, Coriu D, Weiss DT, Makovitzky J, Westermark P | title = Amyloid contained in the knee joint meniscus is formed from apolipoprotein A-I | journal = Arthritis Rheum. | volume = 54 | issue = 11 | pages = 3545–50 | year = 2006 | pmid = 17075859 | doi = 10.1002/art.22201 }}</ref>A wide variety of [[淀粉样变|amyloidosis]] symptoms are associated with rare Apo A1 mutants.

Apo A-I binds to [[脂多糖|lipopolysaccharide]] or [[脂多糖|endotoxin]], and has a major role in the anti-endotoxin function of HDL.<ref>{{cite journal | vauthors = Ma J, Liao XL, Lou B, Wu MP | title = Role of apolipoprotein A-I in protecting against endotoxin toxicity | journal = Acta Biochim. Biophys. Sin. (Shanghai) | volume = 36 | issue = 6 | pages = 419–24 | year = 2004 | pmid = 15188057 | doi = 10.1093/abbs/36.6.419 }}</ref>

In one study, a decrease in apo A1 levels was detected in [[精神分裂症|schizophrenia]] patients' [[腦脊液|CSF]], brain and peripheral tissues.<!--

--><ref name="pmid17938634">{{cite journal | vauthors = Huang JT, Wang L, Prabakaran S, Wengenroth M, Lockstone HE, Koethe D, Gerth CW, Gross S, Schreiber D, Lilley K, Wayland M, Oxley D, Leweke FM, Bahn S | title = Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues | journal = Mol Psychiatry | volume = 13 | issue = 12 | pages = 1118–28 | year = 2007 | pmid = 17938634 | doi = 10.1038/sj.mp.4002108 }}</ref>

=== Epistatic impact of apo A1 ===
Apolipoprotein A1 and APOE interact epistatically to modulate triglyceride levels in coronary heart disease patients. Individually, neither apo A1 nor apo E was found to be associated with triglyceride (TG) levels, but pairwise epistasis (additive x additive model) explored their significant synergistic contributions with raised TG levels (P<0.01).
<ref>{{cite journal | vauthors = Singh P, Singh M, Kaur T | title = Role of apolipoproteins E and A-I: Epistatic villains of triglyceride mediation in coronary heart disease | journal = Int J Cardiol | volume = 134 | issue = 3 | pages = 410–2 | year = 2008 | pmid = 18378026 | doi = 10.1016/j.ijcard.2007.12.102 }}</ref>

=== Factors affecting apo A1 activity ===

Apo A1 production is decreased by [[骨化三醇|calcitriol]], and increased by a drug that antagonizes it.<ref>{{cite journal | vauthors = Wehmeier K, Beers A, Haas MJ, Wong NC, Steinmeyer A, Zugel U, Mooradian AD | title = Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3 | journal = Biochim. Biophys. Acta | volume = 1737 | issue = 1 | pages = 16–26 | year = 2005 | pmid = 16236546 | doi = 10.1016/j.bbalip.2005.09.004 }}</ref>

Exercise or [[羟甲基戊二酸单酰辅酶A还原酶抑制剂|statin]] treatment may cause an increase in HDL-C levels by inducing apo A1 production, but this depends on the G/A promoter polymorphism.<ref>{{cite journal | vauthors = Lahoz C, Peña R, Mostaza JM, Jiménez J, Subirats E, Pintó X, Taboada M, López-Pastor A | title = Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy | journal = Atherosclerosis | volume = 168 | issue = 2 | pages = 289–95 | year = 2003 | pmid = 12801612 | doi = 10.1016/S0021-9150(03)00094-7 }}</ref>

== 交互作用 ==

載脂蛋白A1可與下列蛋白產生[[蛋白質交互作用|交互作用]]：

* {{tsl|en|ABCA1|ABCA1}}<ref name = pmid12084722>{{cite journal | vauthors = Fitzgerald ML, Morris AL, Rhee JS, Andersson LP, Mendez AJ, Freeman MW | title = Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I | journal = J. Biol. Chem. | volume = 277 | issue = 36 | pages = 33178–87 | date = September 2002 | pmid = 12084722 | doi = 10.1074/jbc.M204996200 }}</ref>
* {{tsl|en|GPLD1|GPLD1}}<ref name = pmid11254757>{{cite journal | vauthors = Deeg MA, Bierman EL, Cheung MC | title = GPI-specific phospholipase D associates with an apoA-I- and apoA-IV-containing complex | journal = J. Lipid Res. | volume = 42 | issue = 3 | pages = 442–51 | date = March 2001 | pmid = 11254757 | doi =  }}</ref>and
* {{tsl|en|PLTP|PLTP}}<ref name = pmid9469594>{{cite journal | vauthors = Pussinen PJ, Jauhiainen M, Metso J, Pyle LE, Marcel YL, Fidge NH, Ehnholm C | title = Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: location of a PLTP binding domain in the amino terminal region of apoA-I | journal = J. Lipid Res. | volume = 39 | issue = 1 | pages = 152–61 | date = January 1998 | pmid = 9469594 | doi =  }}</ref>

===Potential binding partners===
Apolipoprotein A1 binding precursor, a relative of APOA-1 abbreviated {{tsl|en|APOA1BP||APOA1BP}}, has a predicted biochemical interaction with {{tsl|en|CARKD||Carbohydrate Kinase Domain Containing Protein}}. The relationship between these two proteins is substantiated by [[cooccurance_across_genomes|cooccurance across genomes]] and [[coexpression|coexpression]].<ref name=STRING>{{cite web |title=STRING: Known and Predicted Protein-Protein Interactions |url=http://string.embl.de/newstring_cgi/show_edge_data.pl?taskId=gboDpgqu9YY_&node1=418518&node2=410384 |deadurl=yes |archiveurl=https://web.archive.org/web/20110718103541/http://string.embl.de/newstring_cgi/show_edge_data.pl?taskId=gboDpgqu9YY_&node1=418518&node2=410384 |archivedate=2011-07-18 }}</ref>The ortholog of CARKD in ''E. coli'' contains a domain not present in any eukaryotic ortholog. This domain has a high sequence identity to APOA1BP. CARKD is a protein of unknown function, and the biochemical basis for this interaction is unknown.
{{TransF}}

===交互作用途徑===
{{StatinPathway_WP430|highlight=Apolipoprotein_A1}}

== 參見 ==
* [[载脂蛋白B|载脂蛋白B]]
* [[心血管疾病|心血管疾病]]
* {{tsl|en|ApoA-1 Milano||ApoA-1 Milano}}

== 參考文獻 ==
{{Reflist|2}}

== 外部連結 ==
* {{MeshName|Apolipoprotein+A-I}}
* [https://www.mabtech.com/knowledge-center/applied-research/apolipoproteins Applied Research on Apolipoprotein-A1]

{{Lipoproteins}}

[[Category:载脂蛋白|A]]